Compare Ascendis Pharma A/S (ASND) vs VICI Properties Inc (VICI) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs VICI Properties Inc — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while VICI Properties Inc trades at $26.11 (market cap $28.64B). The key difference: VICI Properties Inc is the larger of the two by market cap, and VICI Properties Inc pays a 6.92% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | VICI | |
|---|---|---|
Market Cap | $17.74B | $28.64B |
Sector | Health | Real Estate |
52-Week High | $277.18 | $33.93 |
52-Week Low | $163.32 | $25.94 |
Enterprise Value | $18.11B | $45.86B |
Dividend Yield | — | 6.92% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
VICI Properties trades at $26.01, showing modest daily gains. The stock is technically bearish with key support at $25, while fundamentals remain strong with a P/E of 8.91 and robust profitability margins. Recent news highlights concerns over tenant concentration but also underscores the REIT's investment-grade balance sheet and attractive 6.8% dividend yield. Q2 2026 earnings are anticipated on July 29, 2026.
The outlook is mixed: strong cash flows and analyst buy ratings support upside to a $30.75 target, but technical weakness and reliance on Caesars/MGM pose risks. Investors may find value in the discounted valuation if operational stability persists amid sector headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About VICI Properties Inc
VICI Properties is an S&P 500 experiential real estate investment trust (REIT) that owns one of the largest portfolios of market-leading gaming, hospitality, and entertainment destinations, including Caesars Palace and MGM Grand. It utilizes a long-term, triple-net lease model to provide stable, inflation-protected income, serving as the primary landlord for the 'experience economy' while diversifying into non-gaming sectors like wellness, youth sports, and luxury resorts.
Read more on VICI →
